Spero Therapeutics grants CEO $254K cash + $508K RSU, CFO $168K cash + $336K RSU retention awards

Spero Therapeutics, Inc.

CEO Ankit Mahadevia receives $254K cash bonus (Nov 30, 2022) and up to $508K in stock based on performance criteria.
CFO Satyavrat Shukla receives $168K cash bonus (Nov 30, 2022) and up to $336K in stock based on performance criteria.
Awards tied to continued employment through May 31, 2023 and achievement of pipeline, BD, and financial stewardship goals.
Unvested RSUs lapse if performance criteria not met by May 31, 2023; vesting acceleration only in certain change-in-control events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.